retatrutide effects clinical trial Retatrutide: A Multi-Receptor Approach to Weight Management The experimental GLP-1 drug 'reta'

Setting goals beyond the scale can help: Pay attention to positive changes in your blood work, overall energy, sleep, pain, and cravings

Any licensed health care providerincluding primary care physicians, nurse practitioners, physician assistants, and specialists such as endocrinologists, cardiologists, and gastroenterologistscan prescribe GLP-1 medications

Common side effects reported with retatrutide include: Nausea, vomiting, and diarrhoea (most frequent, particularly during dose escalation) Decreased appetite Constipation Injection site reactions Mild increases in heart rate Cagrilintide has demonstrated a generally well-tolerated profile, with gastrointestinal symptoms also being the most commonly reported adverse effects

Q1 2027 FDA Filing Decision: The FDA has 60 days to review the submission for completeness